Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Ebola vaccine doses will be ready in 2015
Vaccination
Trials of ebola vaccines have already begun in the US, UK and Mali.
Parties working together to finalise fastest approach for developing and distributing vaccines

Millions of doses of experimental Ebola vaccines will be available in 2015, the World Health Organisation (WHO) has announced.

The commitment was made during a WHO meeting last week with high-ranking government representatives from Ebola-affected countries and development partners, funding agencies, vaccine manufacturers, civil society and regulatory agencies.

During the meeting, the participants discussed and agreed on how to fast-track testing and deployment of vaccines in ample numbers to impact the Ebola epidemic.

The participants agreed that phase one clinical trials of the most advanced vaccines will be available by December 2014. They also agreed that efficacy trials in affected countries also begin in this timeframe, with protocols adapted to take into consideration safety and immunogenicity results as they become available.

Pharmaceutical companies developing the vaccines committed to scale-up production capacity for millions of doses to be available in 2015, with several hundred thousand to be ready before the end of the first half of the year. Regulatory authorities in both Africa and countries where the vaccines are manufactured committed to supporting this aim by working under extremely short deadlines.

It was also decided that community engagement is key and work should be increased urgently in partnership between local communities international organisations, NGOs and national governments.

WHO say that vaccines may have a major impact on further evolution of the epidemic. All parties will be working together to finalise the quickest approach for developing and distributing vaccines, so that effective treatments and prevention methods are welcomed and shared far and wide by the communities themselves.  

Trials of vaccines have already begun in the US, UK and Mali, and are beginning in Germany, Gabon, Switzerland and Kenya to establish safety and dose level.

Marie-Paule Kieny, WHO's assistant director-general of health systems and innovation, said: "As we accelerate in a matter of weeks a process that typically takes years, we are ensuring that safety remains the top priority, with production speed and capacity a close second."

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.